Technical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable

Similar documents
Derivation and Justification of Safety Thresholds

PQRI Workshop: Leachables and Extractables

Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables. VIII. Quality Control and Specification Setting

Analytical Challenges Presented by Leachables from Sample Container Closure Systems in Drug Products AAPS Discussion Group

Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)

Extractables and leachables: An Introduction

Leachable and Extractable Testing

PDA Midwest Presentation. Extractable/Leachables Overview. Mike Coon, BD Manager May, 2016

Dealing with Extractables & Leachables from a Regulatory Perspective - Design of Extractables & Leachables Studies - Safety Assessment of Leachables

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

Best Practices for Leachables and Extractables Testing

PHARMACEUTICAL TESTING

PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products

Extractables & Leachables. Ophthalmic Drug Products: A Regulatory Perspective Current Industry Challenges and Case Studies

Industry Perspectives on OINDP Regulatory Challenges in Global Environment

November 8, 2018 IPAC-RS SUPPLIER AND PHARMA WORKSHOP. (c) 2018 IPAC-RS

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness

Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods

Teeramanas Tanaekakarapong, a peritoneal dialysis patient

Extractables and leachables: Regulatory requirements for vaccine and biologic products

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY

Perspectives on Method Validation: Importance of Adequate Method Validation

Impurities from degradation of Drug Substances

Analytical Methods Development and Validation

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon

Review Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M.

Guidance for Industry

PRIMARY PACKAGING. Influences the Results of E&L Studies

ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group

Thank You to United States Pharmacopeia for Their Sponsorship and Assistance

Guidance for Industry

Analytical Procedures and Methods Validation for Drugs and Biologics

Investigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

GUIDELINE FOR THE STABILITY TESTING

NOVEL APPLICATIONS AND PRODUCT DESIGNS: DRIVING NEW REQUIREMENTS FOR ASSESSMENT AND SELECTION

How to implement ICH Q3D of elemental impurities in 5 steps

Verification of Compendial Methods

Extractable and Leachable Challenges From a generic injectable drug development perspective

Presentazione: Use of coupled chromatographic analytical. registration of new medicinal products. Relatore: Dr.ssa Federica Bruno

ICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options

Evaluating single-use systems

An Alternative Approach to Quantitative Methods: Limit test for Analysis of Deeming Analytes in Electronic Cigarettes

STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

Safety Qualification Process and Application of Thresholds. Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm

QbD in developing semisolid formulations

OMICS International Conferences

WHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS

ICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP

MDI Manufacturing Services

Cleaning validation of cleanrooms and preparation equipments

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)

FDA Perspective on Standards and Recommendations for Control of Elemental Impurities in Drug Products

Microbiological Consideration for Non-Sterile Pharmaceutical

Perspectives on the PQRI Extractables and Leachables ''Safety Thresholds and Best Practices'' Recommendations for Inhalation Drug Products

Extractable and Leachable Studies of Parenteral Infusion and Transfusion Products

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER

Elemental impurities impact on APIs

Chemical Aspects of Stability Evaluation

Validation & Transfer of Methods for

The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G

A.1 Contents file 4 to 5 A.1 (1)

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review

Contents. Contents (13) 1 Production (23)

Leachables and Extractables Outlook PODP Accomplishments and Next Steps

Container Closure Integrity Testing Method Development and Validation for Pre lled Syringes

DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API)

9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device

of the TTC Douglas J Ball, MS, DABT

Considerations for Ophthalmic Drug Products in Semi-Permeable Packaging

Guidelines for Pharmaceutical Equivalence Requirements

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization

Developing a Phase-Appropriate Extractables and Leachables Program

Documentation requirements for an initial consultation

A STANDARD PROTOCOL for DERIVING and ASSESSMENT of STABILITY. Part 3 Oral Liquid Medicines (Solutions, Emulsions, Suspensions and Syrups)

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

Regulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017

Role of the IPAC-RS GMP Guideline in Promoting OINDP Component Quality Barbara Falco, Kos Pharmaceuticals

Revision of 30 April 2013 draft, 4 November 2013

On the Q&A to the Guideline for Common Technical Documents

Quantitative determination of residual 2-(2-chloroethoxy) ethanol (CEE) in quetiapine fumarate by gas chromatogaraphy

International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW

GMPs for Method Validation in Early Development: An Industry Perspective (Part II)

Manual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:

PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS

DEVELOPING AN IN VITRO RELEASE TESTING (IVRT) METHOD FOR THE VALIDATION OF SEMI-SOLID TOPICAL FORMULATIONS

ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT. Version 4.0. Update revision : May Document Control

ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers

Development of Elemental Impurity risk assessments for existing prescription products

HEALTH DEPARTMENT. On the margin, a seal bearing the national symbol and the words United Mexican States Health Department.

Health Canada's Experience When Implementing the ICH Q3D Elemental Impurity Guidance for NDSs and ANDSs

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Medicines Control Authority of Zimbabwe

API Stability Protocols and. Chris Byrne Tasmanian Alkaloids

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.

Transcription:

Technical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable Dr. Gyula Körtvélyessy UNIDO Honorary Secretary General of the Hungarian Chemical Society Regional Expert Group Meeting 3-5 of October, 2011, Moscow

Definitions Extractable: Any chemical species that can be removed from a packaging component under stressful laboratory conditions Leachable: an extractable that actually migrates into a drug product under normal storage and use conditions Extractable for non-compendial plastics components Leachable for all plastic components contact to the formulation

Extractable-Leachable Best practice: Norwood at all (2006 and 2009) Consult with the manufacturer at the early development stage to identify extractables (if known) To get to know the manufacturing process Basic materials Additives Catalyst Fabrication process and additives Cleaning or washing process of the final part of the device www.elsiedata.com : new database on plastics Selection of the parts and suppliers through risk assessment based on this knowledge

Ingredients in a sulphur-cured elastomer test article

Controlled extraction study Janke s directives (2003) Vigorously but not so aggressively to alter the extractable profile The extraction method should be technically justified and optimized to produce a profile correlate to leachable profile What to test? Valve components Actuator Mouthpiece Metal components if coated and if not coated (oily processing residues) Dichloromethane, Isopropyl alcohol and Hexane Dichloromethane mimics CFC or HFA propellant in MDI Isopropyl alcohol mimics Ethanol as cosolvent Reflux, Soxhlet, Sonification

Controlled extraction study cont. Gas Chromatography/Mass Spectrometry, Liquid chromatography / MS and LC/ UV Diode array detection Forced temperature program, high elution power! Broad UV range Identify Extractable 0.15 µg per day (Safety concern threshold) Confirmed, Confident or Tentative identification categories Quantitative extraction studies with optimized (near the asymptotic level) methods Uncertainty of each method established Validate the extraction and analytical method, acceptance criteria

Validation of Extractable/Leachable Methods Validated according to ICH Guidelines Characteristics of a quantitative impurity test Accuracy, Precision, Specificity, LOQ, Linearity and Range Validation Parameter Acceptance Criteria Characteristics of Limit Tests Specificity and LOD

Soxhlet extraction of the elastomer

Leachable study Use the same analytical methods as in the extractable study According to the stability study protocol, till the end of shelf-life of the product Qualitative and quantitative correlation with extractable exist? Assess the risk for leachable 5 µg per day Develop and validate the method for leachable Develop and validate the method for routine extractable with acceptance criteria Robustness and ruggedness: detection changed from MS to FID, from DAD to UV Recovery and accuracy should be checked by an extratable spiked with known amount of impurities into the product

Correlation of Extractable and Leachable Comprehensive Qualitative Quantitative Multiple batches of drug product Multiple lots of critical container closure components All product orientations Accelerated storage conditions Full shelf-life End of Shelf-Life Profiles Leachable less than or equal to extractable

How to calculate with threshold values Safety concern threshold: 0.15 µg per day Transform it into Analytical Evaluation Threshold (AET): Extractable: µg individual substance per part of the device or g of the construction material of device Leachable: µg individual substance per Canister filled with MDI product

Analytical Evaluation Threshold AET NOT the total number of actuations 250 Homogenous and same construction material /valve

MDI product on the market Analytical Evaluation Thresholds

Regulatory documents for extractable and leachable June 2006 by European Medicines Agency and Health of Canada Guideline on pharmaceutical quality on inhalation and nasal product October 1998 by FDA Metered dose inhalers and Dry powder inhalers drug product 2005 by European pharmacopoeia Preparations for inhalation No 671 Pressurized pharmaceutical preparation No 523 2007 by US pharmacopoeia Aerosols, nasal sprays, metered-dose inhalers and dry powder inhalers No 601 Uniformity of dosage units No 905 Pharmaceutical dosage forms (Aerosols, inhalations) No 1151 2009 by International Organization for Standardization Aerosol drug delivery device design verification -- Requirements and test methods No 20072:2009 September 2006-9 by Product Quality Research Institute Leachable and Extractable Working Group, D. Norwood as Chair Safety threshold and best practice for extractable and leachable in orally inhaled and nasal drug products

Regulations for polymers

Drug Master File for any packaging part Item numbers Source(s) and fabricator(s) for each sub-component Composition and quality of materials of each sub-component (including coating, if appropriate) Citations of compliance of the materials to defined regulations, pharmacopoeia etc. Drawings of each sub-component with precise dimensional measurements Description of any treatment processes such as washing, coating, sterilization Analysis for residual contaminants and residues of surface treatments, washings etc - Control extraction studies for elastomeric and plastic components, also for any coated surfaces - Toxicological evaluation of extractables and residues - Performance characteristics of the sub-component and/or assembled finished item - Acceptance criteria, test methods, and sampling plans

Summary Leachable evaluations should be based on methods/techniques used in controlled extraction studies Analytical methods should be guided by the analytical evaluation threshold calculated from Safety concern Threshold 0.15 µg per day Comprehensive correlation may obviate the need for routine implementation of drug product leachable specifications and acceptance criteria Acceptance criteria for leachables should apply over the proposed shelf life and include quantitative limits for known and new/unspecified leachables

Thank you for your kind attention! If you need any documents k.gyula@chello.hu